首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

市場調查報告書

商品編碼

1491767

循環性腫瘤細胞市場規模、佔有率、成長分析、按產品、按檢體、按技術、按應用、按最終用戶 - 行業預測，2024-2031

Circulating Tumor Cell Market Size, Share, Growth Analysis, By Product, By Specimen, By Technology(CTC Detection ), By Application(Clinical Liquid Biopsy ), By End User - Industry Forecast 2024-2031

出版日期: 2024年06月04日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年，全球循環性腫瘤細胞市場規模為103.2億美元，從2023年的113.8億美元成長到2031年的249.4億美元，預計在預測期內（2024-2031年）將成長。 %。

大多數惡性診斷的突破性進展正在為全球循環性腫瘤細胞（CTC）市場創造充滿希望的市場動力。大多數惡性的盛行率不斷上升，增加了對 CTC 評估等非侵入性診斷工具的需求。兩個主要動機是越來越關注定製藥物治療以及大多數病例早期發現癌症的需要。然而，技術複雜性和標準化願望等障礙阻礙了大規模接受。基於 PCR 和 ELISA 的方法是最常見的產品類型。北美擁有完善的醫療基礎設施並擁有較大的市場佔有率。為滿足不斷變化的醫療需求而進行的持續研究、合作夥伴關係和產品改進是該市場的特徵。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Janssen Diagnostics（Johnson & Johnson）
Sysmex America, Inc.
Qiagen
Roche Diagnostics
BD（Becton, Dickinson and Company）
Macrogenics, Inc.
Personalis, Inc.
ANGLE PLC
ApoCell, Inc.
RareCyte, Inc.
Exosomedx
Grail, Inc.
Invivoscribe Technologies, LLC
Epic Sciences, Inc.
Circulating Biomarkers LLC
ClariCell, Inc.
Thrive Earlier Detection
Ellumen
Hera BioLabs
CellMax Life Technologies

簡介目錄

Product Code: SQMIG35H2232

Global Circulating Tumor Cell Market size was valued at USD 10.32 billion in 2022 and is poised to grow from USD 11.38 billion in 2023 to USD 24.94 billion by 2031, growing at a CAGR of 10.3% during the forecast period (2024-2031).

The breakthroughs in the diagnosis of most malignancies have created promising market dynamics for the worldwide Circulating Tumor Cell (CTC) market. The increasing prevalence of most malignancies drives up demand for non-invasive diagnostic tools such as CTC assessment. Two major motivators are the increasing focus on customized medications and the necessity of early cancer detection for the majority of cases. Massive acceptance is prevented, nevertheless, by obstacles including technological complexity and the desire for standardization. PCR and ELISA-based approaches are the most common types of products. North America's well-established healthcare infrastructure contributes to its large market share. Continuous research, partnerships, and product improvements to meet changing medical needs are what define the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Circulating Tumor Cell Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Circulating Tumor Cell Market Segmental Analysis

The global circulating tumor cell market is segmented into product, specimen, technology, application, end user, and region. Based on product, the market is segmented into Kits & Reagents, Blood Collection Tubes, Devices or Systems. Based on specimen, the market is segmented into Blood, Bone Marrow, other body fluid. Based on technology, the market is segmented into CTC Detection (Immunocapture, Size-based separation, Density Based Separation, Combined Methods), CTC Detection method (SERS, Microscopy, Others), CTC Analysis. Based on application, the market is segmented into Clinical Liquid Biopsy (Risk Assessment, Screening and Monitoring), Research (Cancer Stem Cell, Drug Therapy Development). Based on end user, the market is segmented into Hospitals & Clinics, Research & Academic Institutes, Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Drivers of the Global Circulating Tumor Cell Market

The need for better diagnostic tools has increased due to the rising incidence of cancer worldwide. CTC evaluation has emerged as a valuable and non-invasive technique for cancer tracking and diagnosis. The desire for early cancer diagnosis and the focus on personalized medicine are driving the adoption of CTC technologies in a similar way.

Restraints in the Global Circulating Tumor Cell Market

The primary barrier to widespread acceptance in the industry is the intricacy of technology, and the need for consistency in CTC analysis methods creates difficult circumstances. Furthermore, problems pertaining to the consistency and repeatability of CTC effects hinder its integration into standard medical practice.

Market Trends of the Global Circulating Tumor Cell Market

There has been a noticeable change in favor of incorporating CTC examination into routine medical procedures, driven by its ability to track the course of disease and the response to treatment in real time. The continuous advancement of cutting-edge technology, such as improved molecular detection techniques and microfluidic devices, shows a trend toward increased sensitivity and precision in CTC analysis. Furthermore, the increasing awareness of liquid biopsy techniques in cancer diagnosis highlights the importance of CTCs as useful biomarkers.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Pricing Analysis
Start Up Analysis
Regulatory Landscape
Patent Analysis
Pipeline Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Circulating Tumor Cell Market by Technology

Market Overview
CTC Detection
- Immunocapture
- Size-based separation
- Density-Based Separation
- Combined Methods)
CTC Detection method
- SERS
- Microscopy
- Others
CTC Analysis

Circulating Tumor Cell Market by Application

Market Overview
Clinical Liquid Biopsy
- Risk Assessment
- Screening and Monitoring
Research
- Cancer Stem Cell
- Drug Therapy Development

Circulating Tumor Cell Market by End User

Market Overview
Hospitals & Clinics,
Research & Academic Institutes
Diagnostic Centres

Circulating Tumor Cell Market by Product

Market Overview
Kits & Reagents
Blood Collection Tubes
Devices or Systems

Circulating Tumor Cell Market by Specimen

Market Overview
Blood
Bone Marrow
Other body fluid

Circulating Tumor Cell Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Janssen Diagnostics (Johnson & Johnson)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex America, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BD (Becton, Dickinson and Company)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macrogenics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personalis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ANGLE PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ApoCell, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RareCyte, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exosomedx
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grail, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invivoscribe Technologies, LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Circulating Biomarkers LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ClariCell, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thrive Earlier Detection
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ellumen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hera BioLabs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CellMax Life Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments